The Malaria Testing and Treatment Landscape in the Southern Lao People\u27s Democratic Republic (PDR). by O\u27Connell, Kathryn A. et al.
Dominican Scholar 
Collected Faculty and Staff Scholarship Faculty and Staff Scholarship 
4-25-2017 
The Malaria Testing and Treatment Landscape in the Southern 
Lao People's Democratic Republic (PDR). 







ACTwatch Group, andria.rusk@dominican.edu 
ACTwatch Group 
See next page for additional authors 
https://doi.org/10.1186/s12936-017-1769-0 Survey: Let us know how this paper benefits you. 
Recommended Citation 
O'Connell, Kathryn A.; Vasireddy, Vamsi; Littrell, Megan; Rusk, Andria; ACTwatch Group; and 
Phanalasy, Saysana, "The Malaria Testing and Treatment Landscape in the Southern Lao 




This Article is brought to you for free and open access by the Faculty and Staff Scholarship at 
Dominican Scholar. It has been accepted for inclusion in Collected Faculty and Staff Scholarship by 
an authorized administrator of Dominican Scholar. For more information, please contact 
michael.pujals@dominican.edu. 
Authors 
Kathryn A. O'Connell, Vamsi Vasireddy, Megan Littrell, Andria Rusk, ACTwatch Group, and 
Saysana Phanalasy 
This article is available at Dominican Scholar: https://scholar.dominican.edu/all-faculty/336 
ACTwatch Group and Phanalasy  Malar J  (2017) 16:169 
DOI 10.1186/s12936-017-1769-0
The malaria testing and treatment landscape 
in the southern Lao People’s Democratic 
Republic (PDR)
ACTwatch Group and Phanalasy  
Malaria Journal
ACTwatch Group and Phanalasy  Malar J  (2017) 16:169 
DOI 10.1186/s12936-017-1769-0
RESEARCH
The malaria testing and treatment 
landscape in the southern Lao People’s 
Democratic Republic (PDR)
ACTwatch Group1* and Saysana Phanalasy2*
Abstract 
Background: In the context of national and regional goals to eliminate malaria by 2030, the Center for Malaria Parasi-
tology and Entomology in the Lao PDR is implementing strategies to ensure all malaria cases are detected and appro-
priately treated with first-line artemisinin combination therapy, artemether–lumefantrine (AL). Timely and relevant 
evidence to inform policies and strategies is needed to ensure the most effective and efficient use of resources, and to 
accelerate progress towards elimination goals. A 2015 outlet survey conducted in five provinces of the southern Lao 
PDR was the first of its kind to study the total market for malaria treatments and diagnostics. The sub-national outlet 
survey was designed to describe the market and to assess public and private sector readiness and performance for 
malaria case management. Additionally, key indicators were estimated among private outlets within districts with and 
without a Public Private Mix (PPM) programme.
Results: Over half of anti-malarial stockists were public sector (65.1%). In the private sector, pharmacies most com-
monly stocked anti-malarials, although anti-malarials were also found in private health facilities, drug stores, general 
retailers, and itinerant drug vendors. Nearly all anti-malarial stocking public health facilities had AL (99.5%) and 90.8% 
had confirmatory testing. Fewer than half of anti-malarial stocking private outlets stocked AL (40.8%) and malaria 
testing (43.5%). Chloroquine has not been a first-line treatment for Plasmodium falciparum malaria since 2005 and 
Plasmodium vivax since 2011 yet private sector availability was 77.6% and chloroquine accounted for 62.2% of the 
total anti-malarial market share. AL and confirmatory testing availability were higher in private outlets in PPM (68.1, 
72.6%) versus non-PPM districts (2.5, 12.1%). Chloroquine was available in 63.6% of PPM and 96.7% of non-PPM-district 
outlets, and was the most commonly distributed anti-malarial among private outlets in both PPM (61.7%) and non-
PPM districts (99.1%).
Conclusions: Public sector outlets in the southern Lao PDR are typically equipped to test and appropriately treat 
malaria. There is need to address widespread private sector availability and distribution of chloroquine. The PPM 
programme has improved private provider readiness to manage malaria according to national guidelines. However, 
supporting interventions to address provider and consumer behaviours are needed to further drive uptake.
Keywords: Lao PDR, Case management, Private sector, Public private mix, Chloroquine, ACT, Anti-malarial
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Background
Important gains in malaria control have been achieved 
in recent years in the Lao, People’s Democratic Republic 
(PDR). Malaria admissions and deaths have declined 
substantially since 2000. However, a 2011 outbreak in 
the southern provinces has been associated with a spike 
in cases and deaths. Case numbers have not returned to 
the seasonal low levels observed prior to 2011, suggest-
ing an ongoing outbreak [1]. In 2015, there were over 
48,000 reported confirmed positive malaria cases, up 
from 38,131 cases in the previous year [1, 2]. Approxi-
mately 31% of the Lao PDR’s population of 6.6 million 
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live in areas of high transmission and another 61% live in 
areas of low transmission. The vast majority (95%) of the 
malaria burden is concentrated in the southern five prov-
inces. Plasmodium falciparum makes up 62% of the para-
site species while Plasmodium vivax comprises the other 
38% [2]. Artemether–lumefantrine (AL) was introduced 
as the first-line treatment for uncomplicated P. falcipa-
rum malaria in 2005 and P. vivax malaria in 2011.
The Lao PDR has set the goal of eliminating P. falcipa-
rum malaria by 2025 and all forms of malaria by 2030. 
In line with the World Health Organization’s (WHO) 
Strategy for Malaria Elimination in the Greater Mekong 
Subregion, the dual goal has been set to both interrupt 
transmission of P. falciparum in areas of multidrug resist-
ance as well as reduce malaria transmission in high trans-
mission areas to less than one case per 1000 population 
at risk by 2020 [1, 3].
Detecting and appropriately treating all malaria cases is 
critical to achieving elimination goals in the Lao PDR. In 
order to bolster proper testing and treatment practices, the 
Center for Malaria Parasitology and Entomology (CMPE) 
has devoted significant resources in recent years to ensur-
ing that public health facilities are stocked with appropri-
ate first-line artemisinin combination therapy (ACT) and 
malaria rapid diagnostic tests (RDTs). Malaria diagno-
sis has been free of charge in the public sector since the 
beginning of 2005 [1]. In 2010, CMPE began procuring 
RDTs capable of detecting both P. falciparum and P. vivax 
parasites, which increased the number of reported cases.
CMPE expanded access to appropriate test and treat 
services to the community-level through the train-
ing and equipping of Village Malaria Workers as well as 
some existing Village Health Volunteers for proper test-
ing and treating of malaria in endemic areas. The Com-
munity Health Worker (CHW) programme for malaria 
case management using RDT and ACT was introduced 
in 2005. In 2016, a total of 5825 CHWs with malaria case 
management training and equipment were counted [1]. 
Activities aimed at strengthening the CHW network are 
highly prioritized and are scheduled to receive USD $4.2 
million over the next 5 years [1].
CMPE has also extended access to appropriate malaria 
case management through leveraging the private sec-
tor. The Public Private Mix (PPM) programme com-
menced in 2008 as a way of introducing first-line ACT 
and RDT into the highly utilized private sector. Partici-
pating pharmacies and private for-profit facilities were 
supplied with AL and RDTs through the existing govern-
ment supply chain. Participating outlets were permitted 
to sell the products at a small profit, though many pro-
viders reportedly chose to dispense AL free of charge [4]. 
The PPM pilot initially included 10 private clinics and 85 
pharmacies from 8 districts across 4 provinces. By 2012, 
the programme expanded to 16 clinics and 245 pharma-
cies from 22 districts across 8 provinces [4]. According to 
government policy, only PPM pharmacies are authorized 
to dispense anti-malarials.
In line with the National Strategic Plan, CMPE and 
other implementing partners, will continue to address 
malaria case management gaps that are critical to achiev-
ing progress towards malaria elimination over the next 
5  years. Timely and relevant evidence to inform case 
management policies and strategies is needed to ensure 
the most effective and efficient use of resources, and to 
accelerate progress towards elimination goals. However, 
substantial evidence gaps exist with respect to the total 
market for malaria testing and treatment in the southern 
Lao PDR, including case management readiness and per-
formance of providers across the public and private sec-
tors. Understanding the private sector in the Lao PDR 
will be particularly important given this is an important 
treatment channel [5].
The ACTwatch project is a multi-country research 
project launched in 2008 by Population Services Inter-
national (PSI) and London School of Hygiene and Tropi-
cal Medicine (LSHTM) with support from the Bill and 
Melinda Gates Foundation. The goal of ACTwatch is to 
fill contemporary evidence gaps by collecting malaria 
case management market data on anti-malarial treat-
ments and malaria diagnostics in both the private and 
public sector. ACTwatch provides timely, high quality 
and relevant anti-malarial market data so as to inform 
and monitor national, regional and global malaria case 
management policy, strategy and funding decisions [6, 7].
The 2015 ACTwatch outlet survey was the first of its 
kind to be conducted in the Lao PDR. The objective of 
this paper is to provide practical evidence to inform the 
malaria elimination strategy and policy in the Lao PDR. 
The paper describes the total market for malaria treat-
ments and diagnostics in the five southern provinces of 
the Lao PDR with highest malaria burden. Key indicators 
are presented including a description of the market, read-
iness to test and treat in public and private sectors, anti-
malarial market share, and provider knowledge. Evidence 
on the total market, as well as on outcomes associated 
with the PPM programme, will point to recommenda-
tions for rapidly improving coverage of appropriate 
malaria case management in the southern Lao PDR.
Methods
Design and sampling
A representative cross-sectional outlet survey was con-
ducted amongst a sample of outlets stocking malaria test-
ing and/or treatment in five southern provinces in the 
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Lao PDR (Savannakhet, Champasack, Salavanh, Sekong 
and Attapeu). According to the ACTwatch methodol-
ogy, outlets are included in the survey if they have the 
‘potential’ to sell or distribute anti-malarials or diagnos-
tic testing. This includes outlets that may not typically 
be expected to stock anti-malarial treatments, such as 
general retailers, village shops, or itinerant drug vendors. 
However, it is recognized that in many countries these 
outlets can operate as vendors for anti-malarial commod-
ities, either illegally or/and outside of the formal health 
system. As such, in many instances outlets are included 
in the sample as a means to confirm their role or pres-
ence in a given country’s anti-malarial and diagnostic 
market. These outlets may differ on a country by country 
basis, but overall broad categories are used to define pub-
lic and private sector outlets.
In the Lao PDR, outlets with the potential to sell or dis-
tribute included public health facilities (provincial hos-
pitals, district hospitals and health centers) and CHWs 
(village malaria workers and village health volunteers). 
Private sector outlets included private for-profit health 
facilities and pharmacies. The private for-profit facil-
ity category consisted of private hospitals, clinics and 
diagnostic laboratories. The pharmacy category con-
sisted of clinical pharmacies and level 1, 2 and 3 phar-
macies. Clinical pharmacies are those that offer clinical 
and pharmaceutical services despite only being licensed 
to offer pharmaceutical services. Level 1 pharmacies are 
large, can act as wholesalers and have pharmacists on 
staff to advise patients on treatment. Level 2 pharma-
cies, while smaller, can still act as wholesalers but only 
sometimes have pharmacists on staff to advise patients. 
Level 3 pharmacies are small and the owner, who is not 
a pharmacist, is renting a pharmacy license from a phar-
macist. Informal private sector outlets were also included 
in the outlet survey, including drug stores, general retail-
ers and itinerant drug vendors. Drug stores were defined 
as unregistered rural market or home stalls that primar-
ily sold treatments and were not necessarily staffed by a 
trained pharmacist. General retailers consisted of grocery 
stores and village shops selling fast-moving consumer 
goods. Itinerant drug vendors were unregistered mobile 
drug vendors generally catering to mobile migrant com-
munities. Outlets that did not serve the general public 
were excluded from the outlet survey, however military 
and police facilities that served the general public were 
included.
The primary sampling approach taken for ACTwatch 
outlet surveys entails sampling a set of administrative 
units (geographic clusters) with a population of approxi-
mately 10,000–15,000 inhabitants. Clusters are selected 
with cluster probability of selection proportionate to 
size (PPS). A census of all outlets with the potential to 
sell   or  distribute anti-malarials is then conducted in 
sampled clusters, given a sampling frame for all poten-
tially eligible outlet types is not available. The most 
appropriate administrative unit in the Lao PDR matching 
the desired population size was a village group. The vil-
lage group was an administrative unit with populations 
smaller than districts but larger than individual villages. 
Most village groups include between five and ten villages. 
Village groups were selected with PPS using popula-
tion estimates obtained from the Lao National Statistics 
Centre.
Given this was the first ACTwatch outlet survey imple-
mented in the Lao PDR, and previous information on the 
number of outlets or first-line treatment was not avail-
able, a series of calculations and assumptions were made 
to identify minimum sample size requirements. The sam-
ple size was developed to estimate with precision (±7.5 
percentage points) the proportion of outlets with first-
line anti-malarial treatments available, among outlets 
with anti-malarial(s) in stock on the day of the survey for 
all public health facilities and private for-profit facilities 
and pharmacies. The required sample size was calcu-
lated in three steps: (1) determine the required number 
of anti-malarial-stockists; (2) determine the number of 
clusters (village groups) for the census to arrive at this 
number of outlets; (3) determine the required number 
of village groups. Available information on numbers of 
public and private sector outlets per village group were 
used to determine the optimal number of clusters for the 
outlet survey. National outlet lists provided by the Food 
and Drug Department and Health Care Department were 
used to determine the number of public health facilities 
and private registered outlet types per village group. On 
average, in the Southern Lao PDR there were around 3.3 
public health facilities and regulated private outlets per 
village group. Based on these assumption, a sample size 
of 77 village groups was selected in order to estimate 
key indicators on availability of first-line treatment and 
malaria testing with 95% confidence and a maximum 
tolerable error of 5%. A design effect of 2 was used to 
account for cluster sampling in the context of what was 
anticipated to be a high degree of homogeneity in the 
anti-malarial market within and across clusters.
To estimate indicators within the private sector with 
precision, the boundary for the census of pharmacies 
and private for-profit health facilities was extended to the 
district level. This ‘booster sample’ of formal private sec-
tor outlets covered all pharmacies and private for-profit 
health facilities within 41 of the 42 distributed in the 
five study provinces allowing for a sufficient sample size 
to allow for precise comparisons between these impor-
tant but less common facility types Within each selected 
cluster, a census of all the aforementioned outlets was 
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conducted. To identify outlets, interviewers would walk 
systematically through each of the selected clusters look-
ing for relevant outlets. Lists of registered outlets, such 
as public health facilities or pharmacies, were obtained 
prior to the data collection and used to help identify 
outlets. To identify itinerant drug vendors, congregation 
points or locations were identified using key informant 
interviews. These providers were approached by inter-
viewers and asked if they had already participated in the 
survey to avoid duplication. Outlets were screened to 
assess eligibility for the outlet survey. Outlets were eligi-
ble for a provider interview and malaria product audit if 
they met at least one of three study criteria: (1) one or 
more anti-malarials reportedly in stock on the day of the 
survey; (2) one or more anti-malarials reportedly in stock 
within the 3 months preceding the survey; and/or (3) had 
malaria blood testing (microscopy or RDT).
Measures
The outlet survey was conducted using a paper question-
naire. The questionnaire was translated from English to 
Lao and then back to English to confirm valid transla-
tions in Lao. Outlets meeting eligibility criteria noted 
above were invited to participate in the survey. Follow-
ing informed consent procedures, an audit of all available 
anti-malarial treatments and RDTs was conducted. Anti-
malarial audit information included formulation, package 
size, brand name, active ingredients and strengths, man-
ufacturer, country of manufacture, reported sale/distri-
bution in the week preceding the survey, retail price, and 
wholesale price. The RDT product audit collected similar 
information, but excluded questions on pack size, formu-
lation, strength and active ingredients. In addition to the 
product audit, a series of questions was administered to 
the senior-most provider regarding malaria case man-
agement knowledge and practices, as well as provider 
training and qualifications and reporting on malaria case 
load data (Additional file 1: Survey questionnaire in Eng-
lish, Additional file  2: Survey questionnaire in Lao lan-
guage). Geo-coordinates were recorded for each outlet 
using a handheld Global Positioning System (GPS) unit. 
Up to three visits were made to all outlets to complete 
the screening process, audit, and provider interview, as 
needed (e.g. where outlets were closed or providers were 
not available).
Training and data collection
All standardized training materials were adapted to fit 
within the context of the southern Lao PDR. A 1-week 
training of trainers was held in October 2015, followed by 
a 2-day pilot to test the ACTwatch outlet survey instru-
ments in the Lao PDR context. A 6-day data collector 
training was then held, followed by a 2-day data collector 
field exercise in order to give newly trained data collec-
tors practice with the study methodology and tools. High 
performers identified during data collector training were 
selected for a further 3  days of supervisor and quality 
controller training.
Five data collection teams were created after the con-
clusion of training. Each team was comprised of one 
supervisor, one quality controller and three to four data 
collectors. Two PSI/Lao platform and two research 
agency staff offered higher-level logistical and data qual-
ity supervision. Field operations were supervised and 
managed by  an ACTwatch team-member.
A 4-day double data entry and data coding training was 
also conducted. A supervisor, two coders and ten data 
entry clerks were trained in appropriate coding, transla-
tion and data entry techniques. The supervisor oversaw 
all data coding and entry processes and notified ACT-
watch staff if any issues arose.
Peak malaria transmission season in the  Lao PDR is 
July–October. Due to delays in study approval, data col-
lection took place between November 18th and Decem-
ber 29th, 2015. Upon a data collection team’s arrival to 
a district within a selected cluster, data collector team 
supervisors met with district officials to crosscheck their 
list of public and formal private sector outlets with that of 
the government list. Data collection teams then travelled 
to the selected cluster and met with the village group 
head. These meetings generally yielded sketch maps of 
the villages, which were useful for data collection teams 
during the census process.
A Microsoft Access (Microsoft Corporation, Redmond, 
Washington, USA) database with built-in range checks 
was used to conduct double data entry from physical 
questionnaires shipped from the study area to Vientiane. 
Daily supervisor and data collector monitoring sheets 
were collated in a Microsoft Excel (Microsoft Corpora-
tion, Redmond, Washington, USA) spreadsheet, which 
along with the physical questionnaires, were used to tri-
angulate entered data.
Protection of human subjects
The 2015 outlet survey protocol received ethical 
approval from the National Ethics Committee for Health 
Research in the Lao PDR (approval number 059 NIOPH/
NECHR). Provider interviews and product audits were 
completed only after administering a standard informed 
consent form and provider consent to participate in 
the outlet survey. Providers had the option to end the 
interview, which was conducted in a private place, at 
any point during the outlet survey. Standard meas-
ures were employed to maintain provider confidential-
ity and anonymity. Fieldworker training instructed and 
assessed understanding of these standard precautions 
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for protecting human subjects among all people working 
on the study. All information provided by respondents 
was strictly confidential and used only for study pur-
poses. All data collectors were instructed and monitored 
to ensure that they did not share information about indi-
vidual outlets or providers with community members or 
local leaders. Information about individual outlets was 
not shared with any national authorities. Results were 
not linked to individual providers or outlets. Respondent 
names and outlet names were not stored with the final 
clean data.
Data analysis
Stata 13 (StataCorp, College Station, Texas, USA) was 
used to analyse data imported from the Access database. 
Survey settings were used to account for the study design 
and included sampling weights, calculated as the inverse 
of probability of village group selection.
Standard ACTwatch indicators were calculated [6, 
7]. Briefly, anti-malarials were classified as ACT, non-
artemisinin therapy, and oral or non-oral artemisinin 
monotherapy.
Availability was defined in this study as the proportion 
of outlets stocking at least one anti-malarial, among cen-
sused outlets. Other anti-malarial and RDT availability 
categories were calculated but restricted to those outlets 
where at least one anti-malarial was audited. For exam-
ple, ACT availability (the proportion of ACT-stockists) 
was measured as the number of ACT-stockists in the 
numerator and the number of anti-malarial stockists in 
the denominator.
Market share was defined as the relative distribution 
of the anti-malarials to individual consumers in the week 
preceding the survey. In order to allow for meaningful 
market share comparisons between products, informa-
tion about anti-malarial distribution was standardized 
to the adult equivalent treatment dose (AETD). AETD is 
the amount of active ingredient necessary to treat a 60 kg 
adult according to WHO treatment guidelines [8]. Vol-
umes distributed were calculated by converting provider 
reports on the number of anti-malarials sold in the week 
prior to the survey into AETDs. Volumes were, therefore, 
the number of AETDs sold or distributed by a provider in 
the 7 days prior to the survey. All dosage forms were con-
sidered in measuring volumes so as to provide a complete 
assessment of anti-malarial market share. Private sector 
booster sample outlets were excluded from market share 
calculations to avoid over-estimating the role of the pri-
vate sector.
Median private sector price per AETD was calculated 
for the first-line ACT and for chloroquine, and for RDT 
testing including consultation and service fees. Inter-
quartile range (IQR) was calculated to demonstrate price 
dispersion. Anti-malarial and RDT price was collected in 
Lao Kip and converted to the US dollars based on official 
exchange rates for the 6-week data collection period.
Provider knowledge was assessed by administering 
knowledge questions to the senior most provider at all 
anti-malarial-stockists. The senior-most provider was 
questioned because he or she generally holds the most 
knowledge regarding diagnosis and prescription prac-
tices at the outlet. In all but one case, data collectors 
were able to interview the senior-most provider at eligi-
ble outlets. The one outlet in which the senior-most pro-
vider was not available was dropped from the data set. 
Provider knowledge was assessed in two ways—knowl-
edge of national first-line treatment and dosing regi-
men for uncomplicated P. falciparum/P. vivax malaria 
for a 60  kg adult as well as dosing regimen for uncom-
plicated P. falciparum/P. vivax malaria for a 60 kg adult. 
Dosing regime knowledge assessment components 
included  questions on the number of tablets per dose, 
number of times per day and number of days in the 
regimen.
Among the 41 study districts, there were 25 districts 
with and 16 districts without the PPM programme. PPM 
programme designation for each district was obtained 
from CMPE. Private for-profit facilities or pharma-
cies were defined as being part of the PPM programme 
according to their designated location. Outlets that were 
located in PPM districts were designated as ‘PPM outlets’, 
and those outlets that were located in non-PPM districts 
were defined as ‘non-PPM’ outlets. Only private for-profit 
facilities and pharmacies were classified as PPM or non-
PPM outlets, given these were the outlet types targeted 
by the programme. Other outlet types, such as public 
health facilities and general retailers were excluded from 
the PPM definition. Key private sector indicators includ-
ing availability, anti-malarial market share, and price 
were calculated among the private sector PPM and non-
PPM outlets.
Results
A total of 7586 outlets were screened for availability of 
anti-malarials and/or malaria blood testing services. Of 
screened outlets, 725 were stocking anti-malarials or 
malaria blood testing on the day of the survey or within 
the past 3  months, and 724 were subsequently inter-
viewed, as one eligible respondent was not available for 
interview. A total of 1666 anti-malarial and 483 RDT 
products were audited (Additional file 3: detailed sample 
description).
Availability
Across all screened outlets in the public sector (N = 558), 
97.8% of public health facilities and 34.8% of CHWs stocked 
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at least one anti-malarial on the day of survey. Across all 
screened outlets in the private sector (N = 7028), availabil-
ity of any anti-malarial was 6.5%. Private sector availability 
was highest among pharmacies (70.6%; N = 479) followed 
by private for-profit facilities (36.2%, N = 172), drug stores 
(22.0%, N = 15) and itinerant drug vendors (5.3%, N = 67). 
Of the 6295 general retailers screened, 0.5% stocked at least 
one anti-malarial (Fig. 1).
Market composition
Figure 2 illustrates the relative distribution of outlets with 
at least one anti-malarial in stock on the day of survey 
(N  =  402). Among anti-malarial stockists, 67.2% were 
public sector outlets, made up of CHWs (42.5%) and 
public health facilities (22.6%). 22.8% of anti-malarial 
service delivery points were pharmacies. General retail-
ers and private for-profit facilities each accounted for 6.0 
and 4.3% of the market composition respectively. Itiner-
ant drug vendors accounted for just 1% of the anti-malar-
ial market composition.
Availability of anti‑malarials and blood testing
Table  1 illustrates availability of different types of anti-
malarials and malaria blood testing, among outlets that 
were stocking at least one anti-malarial. Among anti-
malarial stockists in the public sector (N =  236), avail-
ability of the national first-line ACT (AL) was 88.8%, with 
almost universal availability among public health facilities 
(99.5%). Availability among CHWs was 83.1%. In the anti-
malarial stocking private sector (N = 394), 63.3% of pri-
vate for-profit facilities and 51.7% of pharmacies stocking 
at least one anti-malarial had AL in stock. All AL available 
in the public and private sectors was considered quality-
assured given that all audited AL products were listed 
on the World Health Organization’s pre-qualification list 
and/or the Global Fund list of approved anti-malarials.
Availability of chloroquine among anti-malarial stock-
ing public health facilities was 4.6 and 19.2% among 
CHW. In the private sector, 77.6% of all anti-malarial 
stockists had chloroquine available. Chloroquine avail-
ability was highest among anti-malarial stocking general 
retailers (96.9%), followed by pharmacies (74.6%) and pri-


























































Fig. 1 Percentage of all screened outlets with at least one anti-malarial in stock on the day of the survey
N=402Public Health Facility
Community Health Worker





Fig. 2 Anti-malarial market composition
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Primaquine was generally not available across the pub-
lic or private sector, with the exception of anti-malarial 
stocking public health facilities (6.7%). Of the 7586 out-
lets screened, only one box of oral artemisinin monother-
apy was found.
Among public health facilities, 90.8% of anti-malarial 
stockists had malaria blood testing; 85.4% had RDTs in 
stock on the day of survey and 23.1% had malaria micros-
copy. Among CHWs, 78.4% had RDTs in stock on the day 
of survey. Within the private sector, malaria blood testing 
was available in 77.0% of private for-profit facilities and 
55.7% of pharmacies, and typically stocked RDTs.
Anti‑malarial market share
Figure  3 shows the relative anti-malarial market share in 
the public and private sector. All anti-malarials report-
edly distributed in the southern Lao PDR were either AL 
or chloroquine, and most anti-malarials distributed were 
chloroquine treatments (62.2%). Almost all the chloroquine 
distributed was through the private sector. In contrast, AL 
was almost exclusively distributed by the public sector.
The public sector accounted 32.3% of the total anti-
malarial market share, including public health facilities 
(23.4%) and CHWs (8.9%). Private sector market share 
was 64.5 and 49.9% of all anti-malarials distributed were 
distributed by pharmacies. Private for-profit facilities and 
general retailers each accounted 7.2 and 6.6% of the mar-
ket share, respectively.
Provider anti‑malarial treatment knowledge
Table 2 illustrates provider knowledge to correctly state 
the national first-line treatment for uncomplicated P. 
falciparum or P. vivax malaria. Provider knowledge 
was 77.9% in the public sector and 40.4% in the pri-
vate sector. Correct knowledge of the dosing regimen 
was 58.2% in the public sector (N  =  255) and 30.2% 
in the private sector (N  =  424). Provider knowledge 
was highest among public health facilities regarding 
the first-line treatment (89.5%) and first-line dosing 
regimen (73.0%). Among pharmacies, 49.5% could cor-
rectly state the first-line treatment for P. falciparum or 
P. vivax malaria.
Chloroquine insights
Most of the chloroquine distributed was in tablet formu-
lation (94.8%), and other formulations included injections 
(5.2%) and syrups (<1%). The most commonly available 
chloroquine product was  Maraquine®, a tablet produced 
in the Lao PDR by CBF pharmaceuticals.  Maraquine® 
accounted for 74.9% of all audited chloroquine products 
and for 50.5% of all anti-malarials distributed. Amongst 
all anti-malarial stocking private sector outlets, 28.9% of 
providers reported chloroquine was the most effective 
treatment for uncomplicated malaria. 32.7% of private 
sector providers reportedly recommended chloroquine 
most often for treatment of uncomplicated malaria in 
adults (Additional file 4).
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Key indicators among private sector outlets in PPM 
and non‑PPM districts
This sub-section presents results among anti-malarial 
stockists located in designated PPM districts and in non-
PPM districts (Table 3). Among the 264 private pharma-
cies and for-profit health facilities in PPM districts, 68.1% 
were stocking the AL and 72.6% were stocking malaria 
blood testing. Availability of AL in 101 pharmacies and 
private clinics in outlets located in non-PPM districts 
was 2.5%. Only 12.1% of pharmacies and private clin-
ics in non-PPM districts had any malaria blood testing. 
96.7% of anti-malarial stockists in non-PPM districts 
were stocking chloroquine compared to 63.6% in PPM 
districts.
Provider knowledge of the first-line treatment for 
uncomplicated P. falciparum or P. vivax malaria was 
65.0% in private sector outlets in PPM districts and 15.0% 
in the non-PPM districts. In PPM districts, 51.0% of pro-
viders correctly stated the first-line dosing regimen for 
uncomplicated P. falciparum or P. vivax compared with 
only 6.1% of providers in private sector non-PPM district 


















































Fig. 3 Anti-malarial market share
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or regulatory visit within the past year was 74.5% in pri-
vate sector outlets in PPM districts and 17.0% in non-
PPM districts.
AL was reportedly provided free-of-charge in private 
sector PPM district outlets. The retail price of chloro-
quine was the same ($0.62) in private sector outlets in 
PPM and non-PPM districts. In PPM districts, RDTs 
were provided free-of-charge in the private sector. The 
median price of an RDT in non-PPM district private sec-
tor outlets was $3.12.
Figure  4 illustrates the total anti-malarial distribution 
among private for-profit facilities and pharmacies located 
within the PPM and non-PPM districts. Chloroquine dis-
tribution was 99.1% among private sector outlets located 
in the non-PPM districts and 61.7% in outlets located in 
the PPM district. Distribution of AL in the week prior to 
the survey was only observed among the private sector 
outlets located in PPM districts (38.3%).
Discussion
The 2015 outlet survey was the first anti-malarial market 
survey of its kind implemented in the southern Lao PDR. 
The outlet survey provided a complete picture of the 
malaria testing and treatment landscape across the public 
and private sectors with information on availability, price 
and market share as well as provider knowledge. The data 
show strong public sector readiness for proper malaria 
case management. Findings point to recommendations 
for rapidly improving coverage of appropriate malaria 
case management by reducing availability and market 
share of chloroquine in the private sector and to expand 
the PPM programme.
Public sector readiness for appropriate malaria case 
management
Findings from the 2015 ACTwatch outlet survey show 
high public sector readiness for appropriate malaria case 
management in the southern Lao PDR. Nearly all public 
health facilities stocked the national first-line ACT, and 
confirmatory testing was available in over 90% of anti-
malarial stocking public facilities.
The reach of the public sector has been extended to the 
community-level through the training and equipping of 
village malaria workers and village health volunteers with 
malaria case management skills and supplies. CHWs are 
playing an important part in provision of malaria case 
management services. They accounted for over 40% of 
all anti-malarial stockists, and distributed nearly 10% of 
all anti-malarials. Maintaining a network of trained and 
equipped CHWs is part of the strategy in the Lao PDR 
for achieving high malaria case management coverage 
and ultimately malaria elimination. Key challenges to be 
addressed as the Lao PDR attempts to achieve its goal of 
eliminating malaria by 2030 include gaps in CHW moti-
vation and retention, training and maintaining supervi-
sion [1]. Results from this outlet survey suggest that in 
addition to these challenges, the availability of the non-
first-line drug, chloroquine, must be addressed as this 
was available among one in five CHWs.
Primaquine is included in the national treatment guide-
lines as part of the first-line treatment for P. falciparum/P. 
vivax along with AL [9]. The results showed how avail-
ability of primaquine was negligible across all the pub-
lic sector. At the time of the survey, primaquine had not 
been widely procured or distributed due primarily to 
Table 3 Key Indicators among pharmacies and private for-
profit health facilities in PPM versus non-PPM districts
AL artemether–lumefantrine, AETD adult equivalent treatment dose, IQR 
interquartile range









Any national first-line 
ACT (AL)
68.1 2.5
(59.7, 75.4) (0.9, 6.8)
Chloroquine 63.6 96.7
(56.5, 70.2) (92.3, 98.6)
N = 275 N = 110
Any confirmatory testing 72.6 12.1













Correctly state the first-
line dosing regimen 








Report receiving a super-
visory or regulatory visit 









National first-line ACT 
(AL) AETD #
$0.00 $0.00
[0.00–0.00] (516) [0.00–0.00] (3)
Chloroquine AETD # $0.62 $0.62
[0.62–0.62] (173) [0.47–0.62] (103)
Rapid diagnostic test $0.00 $3.12
[0.00–0.25] (216) [2.50–3.75] (38)
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concerns of adverse health reactions in patients with glu-
cose-6 phosphate dehydrogenase (G6PD) deficiency. Two 
primaquine products were audited in the 2015 outlet 
survey and these were found in public district hospitals. 
The availability of primaquine in these outlets was likely 
due to a 2015 WHO-supported pilot study, which was 
conducted to assess G6PD testing and primaquine dis-
pensing capabilities at selected district hospitals in three 
provinces. The presence of these products likely reflect 
leftover stock from the pilot study. Wider procurement 
of G6PD tests and primaquine is planned for 2016 as the 
national strategy expands to introduce primaquine more 
widely to treat P. falciparum and radically cure P. vivax 
infections in patients without G6PD deficiency [1, 10].
Role of the private sector in appropriate malaria case 
management
The private sector plays an important role in malaria 
case management in the southern Lao PDR, as results 
from this 2015 outlet survey show that the private sec-
tor was responsible for approximately 60% of all anti-
malarial distribution, a finding corroborated by other 
population based research [5]. Indeed, the private sector 
has played a predominant role in malaria case manage-
ment in other countries in the Greater Mekong Subre-
gion (GMS) region, including neighboring Cambodia [11, 
12]. In the Lao PDR, the private sector for malaria case 
management includes both formal, regulated outlet 
types like private for-profit facilities and pharmacies as 
well as informal, unregulated outlet types such as drug 
stores, general retailers and itinerant drug vendors. Phar-
macies were the most common type of private outlet 
stocking anti-malarials during the 2015 outlet survey, and 
accounted for nearly one in four anti-malarial stockists.
The private sector was generally less well-equipped to 
test and appropriately treat malaria infections as com-
pared with the public sector. Fewer than half of anti-
malarial-stocking private sector outlets were stocking 
the national first-line ACT, and fewer than half had con-
firmatory testing available. The majority of private sector 
outlets had the non-first-line drug, chloroquine, in stock.
Widespread availability and use of chloroquine
Replaced by AL as the first-line treatment for P. falci-
parum in 2005 and P. vivax in 2011, chloroquine is now 
part of the national treatment guidelines as a second-
line treatment for uncomplicated P. vivax, Plasmodium 
ovale and Plasmodium malariae infections. However, the 
availability of the second-line drug, chloroquine, should 
be limited, and with the drug found primarily in public 
health facilities equipped to detect and manage AL treat-
ment failure. The results from this outlet survey illustrate 
how 10 years after the change in first-line treatment for P. 
falciparum and 5 years after the change in first-line treat-
ment of P. vivax, chloroquine remained widely available 
and distributed, particularly in the private sector. The 
widespread popularity of chloroquine has been docu-
mented elsewhere [13], and its common presence on the 
market suggests it is being distributed as a first-line for 
treatment of uncomplicated malaria.
One driver of chloroquine popularity in the Lao PDR 
could be the accessibility of  Maraquine®, an inexpensive, 
chloroquine tablet pre-packaged for individual treat-
































Fig. 4 Anti-malarial market share within pharmacies and private for-profit health facilities in PPM versus non-PPM districts
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(see Additional file 5). The Lao script makes the packag-
ing understandable and recognizable to providers and 
potential customers alike.  Maraquine® accounted for 
three-quarters of all chloroquine audited during the out-
let survey, and accounted for half of all anti-malarials dis-
tributed in the southern Lao PDR. As a widely available 
product,  Maraquine® represents a significant roadblock 
to AL uptake in the Lao PDR’s private sector. Further 
research is required to understand Lao consumer and 
provider preferences for this product, and new strategies 
are necessary to curtail the consumption of chloroquine 
and promote the use of the recommended first-line treat-
ments, especially in the private sector.
Public private mix
Significant efforts have been made in the southern Lao 
PDR to engage the private sector towards improving 
provider practices. The PPM was launched in 2008 with 
the aim of supporting, rather than discouraging phar-
macies and for-profit health facilities to manage malaria 
cases appropriately. As such, the PPM programme has 
expanded access to proper testing and treatment in the 
highly utilized private sector [4]. On a promising note, 
the 2015 outlet survey demonstrated that the PPM pro-
gramme had higher availability of first-line treatment 
and confirmatory blood testing as compared with pri-
vate outlets that were not part of the PPM programme. 
In 2015, nearly all of the AL distributed by the private 
sector was distributed by outlets located in the desig-
nated PPM districts, and private sector availability of 
confirmatory testing was largely restricted to PPM dis-
tricts. This suggests the PPM programme has potential 
for wider reach and impact with the addition of sup-
porting interventions to address provider and consumer 
behaviour.
Despite high coverage with training and supervision, 
as well as moderate levels of provider knowledge regard-
ing first-line treatment, chloroquine was still commonly 
stocked and distributed by these PPM providers. This 
suggests a delay in the uptake of subsidized anti-malari-
als, a finding that has been widely documented by other 
countries in the region [14–16]. Cambodia provides 
an example of a programme with a long history of sub-
sidized first-line treatment in the private sector, and 
through an increasingly regulated private sector  chan-
nel. Repeated outlet surveys have shown that while ACT 
availability has increased, market share has been slower 
to follow suit [17]. Evidence has pointed to the impor-
tance of necessity of considering provider and consumer 
factors that may influence first-line treatment uptake, as 
well as the national regulatory environment.
The market share findings point to the need for new 
strategies, or an intensification of existing ones, to 
completely remove chloroquine from the market. One 
important barrier to consider is the recommended price 
of the subsidised AL treatment. Providers participating 
in the PPM project may lack adequate financial incen-
tives as compared with other subsidy models [18–21]. As 
part of the PPM programme, providers are permitted to 
charge 1000 Lao Kip ($0.12) for a treatment dose of AL 
and 2000 Lao Kip ($0.25) for an RDT [4]. By comparison, 
the median price of a treatment dose of chloroquine was 
$0.62. Although private sector providers may be stock-
ing AL, they may be financially incentivized to dispense 
chloroquine given the profit margins they make, espe-
cially in light of the evidence that they typically distrib-
ute AL free-of-charge. Providers have reported that they 
can offset free distribution of AL by making profits on 
accompanying goods including vitamins and paraceta-
mol, suggesting that profit is indeed important [4]. Future 
strategies may want to consider addressing provider 
financial incentives as well as consumer willingness to 
pay.
There is also likely a need for supporting interventions 
to drive consumer awareness and demand for AL [21]. 
Indeed, studies have suggested that customer demand 
influences retailer ACT dispensing behaviour [22], such 
that the odds of a patient receiving first-line treatment 
was found to be significantly associated with patient 
demand across both public and private sector facili-
ties [23]. However, in general very little is known about 
malaria treatment-seeking behaviour and drivers of 
consumer behaviour in the Lao PDR. Though some key 
reviews were published in the 1990s [24, 25], evidence 
gaps exist. Effective strategies to drive demand for ACT 
will require additional evidence about consumer prefer-
ences and behaviours.
Oral artemisinin monotherapy
Oral artemisinin monotherapy poses a serious threat to 
the continued efficacy of artemisinins in the Lao PDR 
and across the region, and as such this anti-malarial was 
banned in the Lao PDR in 2008. This ban has been spo-
radically enforced by the Food and Drug Department. In 
addition to ban enforcement, the promotion of free first-
line ACT, initially in the public sector and now through 
the PPM programme, has been the main tool used to 
reduce the availability of oral AMT in the Lao PDR.
Previous studies have documented availability of oral 
artemisinin monotherapy in the private sector of GMS 
countries, including the Lao PDR [26]. Over 7500 outlets 
were screened during the 2015 outlet survey and just one 
box of oral artemisinin monotherapy (artesunate tablets) 
was found. Outlet survey results were consistent with 
recent research that has demonstrated a marked decrease 
in oral artemisinin monotherapy availability over time 
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[13]. The removal of oral artemisinin monotherapy from 
the market in the Lao PDR is a success shared by neigh-
boring Cambodia [12], but this remains a serious prob-
lem in another GMS country, Myanmar [27].
Limitations
The ACTwatch outlet survey design has limitations that 
have been documented elsewhere [6, 28]. Specific to the 
outlet survey in the Lao PDR, data collection was con-
ducted just after peak malaria season (July–October), 
between mid-November and the end of December, 2015. 
Outlet surveys are ideally conducted during peak trans-
mission season to avoid fluctuations in stocking key com-
modities that may occur outside of peak season.
The outlet survey entails an audit of all available malaria 
commodities. Providers may have chosen to hide certain 
anti-malarial products. However, similar results were 
obtained through use of a mystery client study design 
implemented in the southern Lao PDR [13], suggesting 
that the outlet survey findings regarding very low levels 
of oral artemisinin monotherapy availability are valid.
The outlet survey was not designed to evaluate the 
PPM programme. PPM district status was determined 
post-data collection and analyses examined private sec-
tor readiness and performance in districts with and with-
out the PPM programme. More rigorous evaluation of 
the PPM programme is needed, with a study designed to 
measure implementation strength and to compare out-
lets that are designated as PPM and non-PPM.
This outlet survey was also not explicitly designed 
to evaluate the malaria CHW programme. CHWs in 
selected clusters were screened to assess availability of 
malaria testing and treatment regardless of reported 
malaria case management training. While most CHWs 
approached were either Village Malaria Workers or 
Village Health Volunteers trained and equipped for 
malaria test and treat services, it is feasible that some 
Village Health Volunteers screened were not part of the 
malaria programme. This may have artificially increased 
the total number of CHWs included in the denominator 
therefore deflating estimates of the indicator showing 
the availability of any anti-malarial, among all screened 
CHWs.
The most senior provider was interviewed at each 
outlet for this survey. Senior-most providers were inter-
viewed as they are generally in the best position to 
provide the most accurate reports of price, sales, avail-
ability, stock outs and service readiness. Some bias could 
have been introduced in that key indicators on provider 
knowledge only reflect answers from these better trained 
providers. Therefore, knowledge of first-line treatment 
and appropriate regimen may have been lower if lower-
level providers were interviewed for this survey.
While all of the ACT that was audited in the Lao PDR 
was quality-assured, it should be acknowledged that this 
quality-assurance status granted by regulatory authori-
ties does not necessarily preclude manufacturing quality 
failures or prevent conditions or practices that may lead 
to drug degradation over time. Moreover, anti-malarial 
treatments that have not been granted pre-qualification 
status or regulatory approval may be safe and efficacious. 
Nonetheless, quality-assurance status has been associ-
ated with high quality medicines in field drug quality 
studies [22]. Further research in the Lao PDR is necessary 
to address the quality of anti-malarial treatments and 
complement previous evidence on this topic [13].
Finally, while the current outlet survey provided supply 
side data on the anti-malarial and diagnostic markets of 
the southern Lao PDR, further information is merited to 
understand the demand side which this outlet survey did 
not investigate. A malaria indicator survey implemented 
in the Lao PDR would provide important and comple-
mentary evidence to the data presented herein.
Conclusions
Public sector outlets in the southern Lao PDR are typi-
cally equipped to test and appropriately treat malaria 
according to national treatment guidelines. However, 
the private sector is responsible for the majority of anti-
malarial distribution. As such there is need to address the 
widespread private sector availability and distribution of 
the non-first-line drug, chloroquine. Evidence suggests 
that the PPM programme approach has been successful 
in introducing first-line ACT and RDTs and improving 
readiness of private providers to manage malaria accord-
ing to national guidelines. However, despite provision 
of training, supervision and key commodities, private 
providers continue to stock and distribute chloroquine. 
Supporting interventions to address provider and con-
sumer behaviours are needed to drive uptake of first-line 
treatment.
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